Mexico push into advanced cell therapy research gains momentum

A Mexicali collaboration between GIOSTAR Mexico and Universidad del Valle de México put postgraduate students into a published study on NK cell therapy for solid tumors. The project highlights how Mexico could move beyond medical tourism and build a stronger role in regenerative medicine research.

Why it matters: - Mexico has an opportunity to expand from a destination for medical services into a contributor to advanced cellular medicine research. - Academic-private collaborations can build specialized scientific talent, strengthen research capacity, and increase Mexico's role in regenerative medicine and cancer immunotherapy. - The work in Mexicali shows how local institutions can help shape the evidence base for future cell therapies.

What happened: - GIOSTAR Mexico and Universidad del Valle de México (UVM), Campus Mexicali, collaborated on a research project involving postgraduate students. - The project examined Natural Killer (NK) cell therapy for solid tumors. - The resulting paper, Efficacy of Adoptive Cell Therapy with Natural Killer Cells in Cases of Solid Tumors, was published in the Journal of Oncology Research and Therapy on August 7, 2026. - On September 22, UVM hosted a ceremony recognizing the students' contributions to the published research. - University leadership, M.C. Diana Esquivel and Alejandro Gutierrez attended the event and presented certificates of recognition.

The details: - M.C. Diana Esquivel, Chief Scientific Officer, led the project with researchers and participating postgraduate students. - The team reviewed existing clinical evidence on adoptive NK cell therapy in lung, breast and colorectal cancers. - The review followed PRISMA guidelines. - The research screened 21,554 records across 20 years of clinical literature. - Twenty studies met the inclusion criteria. - Fourteen studies reported statistically significant differences in at least one clinical outcome. - Reported outcomes included overall survival, progression-free survival, tumor response and quality of life. - The review found variations in cell sources, laboratory protocols, doses and treatment schedules. - The paper identifies NK cell therapy as a potential complementary approach. - The review calls for larger multicenter clinical trials and standardized research protocols. - The findings do not establish NK cell therapy as a replacement for conventional cancer treatment.

Between the lines: - The project is as much about workforce development as it is about science. - Postgraduate students at UVM Campus Mexicali gained experience in literature analysis, research methodology, evidence evaluation and scientific publication. - The collaboration suggests Mexico can compete not only by delivering care, but also by contributing data, training and expertise to specialized medical fields. - NK cell immunotherapy remains an emerging area where international collaboration still matters.

What's next: - Further research will need larger trials and more consistent protocols before NK cell therapy can move closer to standard clinical use. - Continued academic-private partnerships could help Mexico build more research capacity in advanced cell therapies. - The broader goal is stronger international recognition for Mexico as a source of medical innovation, not just medical tourism.

The bottom line: - The Mexicali project is a small but concrete example of how Mexico could build a larger role in the future of cellular medicine.